Kingsway Clinical Research

Etobicoke, Ontario M8X1Y9

0 studies enrolling now · 18 studies all time

What they study most

Alopecia Areata, Atopic, Atopic Dermatitis, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic, Moderate-to-severe Atopic Dermatitis, Non-segmental Vitiligo, Plaque Psoriasis

Studies at this site

• A Study of Barzolvolimab in Patients With Prurigo Nodularis — Running, not enrolling
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) — Completed
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — Completed
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Running, not enrolling
• A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis — Completed
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) — Completed
• Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo — Completed
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) — Completed
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis — Completed